MedPath

National Heart, Lung, and Blood Institute

National Heart, Lung, and Blood Institute logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Diet, Genetics, and CVD Risk Factor Response in Blacks

Completed
Conditions
Cardiovascular Diseases
Heart Diseases
First Posted Date
2004-03-15
Last Posted Date
2016-07-29
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00079703

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies

Phase 2
Completed
Conditions
Bone Marrow Transplant Rejection
Hematologic Malignancies
Interventions
Device: allogeneic hematopoietic stem cell transplantation
First Posted Date
2004-03-10
Last Posted Date
2015-10-26
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
50
Registration Number
NCT00079391
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia

Phase 2
Completed
Conditions
Chronic Myelogenous Leukemia
Chronic Myelomonocytic Leukemia
First Posted Date
2004-03-10
Last Posted Date
2017-07-02
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
7
Registration Number
NCT00079313
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Molecular Epidemiology of Myocardial Infarction and Stroke in Older Adults - Ancillary to CHS

Completed
Conditions
Coronary Disease
Cardiovascular Diseases
Heart Diseases
Cerebrovascular Accident
Myocardial Infarction
First Posted Date
2004-03-01
Last Posted Date
2008-07-24
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00078429

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

Phase 3
Completed
Conditions
Multiple Myeloma
Interventions
Procedure: One Autologous Transplant
Procedure: Second Autologous Transplant
Procedure: Non-Myeloablative Allogeneic Transplant
Behavioral: Observation
First Posted Date
2004-01-13
Last Posted Date
2021-11-01
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
710
Registration Number
NCT00075829
Locations
🇺🇸

DFCI/Brigham & Women's, Boston, Massachusetts, United States

🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

and more 33 locations

Technical Development of Strain Rate Echocardiography

Completed
Conditions
Echocardiography, Doppler
First Posted Date
2004-01-12
Last Posted Date
2017-07-02
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
125
Registration Number
NCT00075920
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation

Phase 2
Completed
Conditions
Healthy
Interventions
First Posted Date
2004-01-09
Last Posted Date
2018-02-07
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
8
Registration Number
NCT00075335
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy

Completed
Conditions
Cardiomyopathy, Hypertrophic
First Posted Date
2003-12-23
Last Posted Date
2008-03-04
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
50
Registration Number
NCT00074880
Locations
🇺🇸

National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States

Genomewide Search for Loci Underlying Metabolic Syndrome

Completed
Conditions
Heart Diseases
Hypertension
Cardiovascular Diseases
Obesity
Hyperinsulinism
Metabolic Syndrome X
Insulin Resistance
First Posted Date
2003-12-15
Last Posted Date
2019-02-11
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00074451

A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)

Phase 2
Completed
Conditions
Myelodysplastic Syndromes
First Posted Date
2003-11-13
Last Posted Date
2008-03-04
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
132
Registration Number
NCT00072969
Locations
🇺🇸

National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath